Relmada Therapeutics, Inc. (RLMD)

Market Cap	68.02M
Revenue (ttm)	n/a
Net Income (ttm)	-157.04M
Shares Out	30.10M
EPS (ttm)	-5.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	339,092
Open	2.25
Previous Close	2.24
Day's Range	2.12 - 2.32
52-Week Range	1.81 - 38.68
Beta	0.16
Analysts	Buy
Price Target	11.60 (+413.27%)
Earnings Date	May 4, 2023

About RLMD

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: RLMD

Analyst Forecast

According to 12 analysts, the average rating for RLMD stock is "Buy." The 12-month stock price forecast is $11.6, which is an increase of 413.27% from the latest price.

Price Target

$11.6

(413.27% upside)

Analyst Consensus: Buy